PURPOSE: to retrospectively determine the long-term outcome of adult intracranial ependymoma patients treated with surgery, reoperation, and postoperative radiation therapy. MATERIAL AND METHODS: 61 patients were treated at our institution between 1980 and 2004. Forty patients had World Health Organization (WHO) Grade II ependymoma, and 21 patients had Grade III ependymoma. The median age was 34 years. The majority of patients were female (59%), and 35 had gross total resections (60%). Eighteen patients were reoperated, 15 only once but 2 twice and one six times. Survival times following reoperation was mostly short but some of them reached more than 5 or 10 years. Postoperative radiation therapy was delivered to 31 patients postoperative (55.4%) and to 5 after reoperation, a median total dose of 54 Gy. RESULTS: The median follow-up of surviving patients was 10.6 years. The 5-year and 10-year disease free survival rates for all patients were 50% and 32.9% respectively. The 5-year and 10-year overall survival rates for all patients were 57.1% and 39.4%, respectively. A statistically significant effect on prognosis was observed with WHO tumour grade as well as with MIB-1 labelling index. Subtotal resection predicted a worse overall survival, but this failed to reach statistical significance. No statistically significant effect on prognosis was observed with tumour location and radiation therapy. CONCLUSION: In our experience the use of radiotherapy in adult, intracranial WHO Grade II ependymoma patients had no significant effect on prognosis. Radical surgery and eventual reoperation seems to be more favorable.
PURPOSE: to retrospectively determine the long-term outcome of adult intracranial ependymomapatients treated with surgery, reoperation, and postoperative radiation therapy. MATERIAL AND METHODS: 61 patients were treated at our institution between 1980 and 2004. Forty patients had World Health Organization (WHO) Grade II ependymoma, and 21 patients had Grade III ependymoma. The median age was 34 years. The majority of patients were female (59%), and 35 had gross total resections (60%). Eighteen patients were reoperated, 15 only once but 2 twice and one six times. Survival times following reoperation was mostly short but some of them reached more than 5 or 10 years. Postoperative radiation therapy was delivered to 31 patients postoperative (55.4%) and to 5 after reoperation, a median total dose of 54 Gy. RESULTS: The median follow-up of surviving patients was 10.6 years. The 5-year and 10-year disease free survival rates for all patients were 50% and 32.9% respectively. The 5-year and 10-year overall survival rates for all patients were 57.1% and 39.4%, respectively. A statistically significant effect on prognosis was observed with WHO tumour grade as well as with MIB-1 labelling index. Subtotal resection predicted a worse overall survival, but this failed to reach statistical significance. No statistically significant effect on prognosis was observed with tumour location and radiation therapy. CONCLUSION: In our experience the use of radiotherapy in adult, intracranial WHO Grade II ependymomapatients had no significant effect on prognosis. Radical surgery and eventual reoperation seems to be more favorable.
Authors: Thomas E Merchant; Jesse J Jenkins; Peter C Burger; Robert A Sanford; Scot H Sherwood; Dana Jones-Wallace; Richard L Heideman; Stephen J Thompson; Kathleen J Helton; Larry E Kun Journal: Int J Radiat Oncol Biol Phys Date: 2002-05-01 Impact factor: 7.038
Authors: W Wagner; P Schüller; N Willich; O Schober; S Palkovic; C Morgenroth; P Bartenstein; F J Prott; U Niewöhner Journal: Strahlenther Onkol Date: 1995-03 Impact factor: 3.621
Authors: Stefan Wolfsberger; Ingeborg Fischer; Romana Höftberger; Peter Birner; Irene Slavc; Karin Dieckmann; Thomas Czech; Herbert Budka; Johannes Hainfellner Journal: Am J Surg Pathol Date: 2004-07 Impact factor: 6.394
Authors: J Guyotat; F Signorelli; S Desme; D Frappaz; G Madarassy; M Fevre Montange; A Jouvet; Ph Bret Journal: J Neurooncol Date: 2002-12 Impact factor: 4.130
Authors: P D Delgado-López; E M Corrales-García; E Alonso-García; R García-Leal; R González-Rodrigálvarez; E Araus-Galdós; J Martín-Alonso Journal: Clin Transl Oncol Date: 2019-03-13 Impact factor: 3.405